Expanding buprenorphine access in the United States requires evidence-based decision-making that considers both the drug's potential dangers and its potential benefits. Risks associated with buprenorphine misuse and diversion highlight the need for careful, ongoing evaluation during each stage of increased access.
M.Pierceet al. “Impact of Treatment for Opioid Dependence on Fatal Drug-Related Poisoning: A National Cohort Study in England,”Addiction111, no. 2 (2016): 298–308.
See e.g. F.Schulte and D.Donovan, “The ‘Bupe’ Fix,”Baltimore Sun, December16, 2007, available at <http://www.baltimoresun.com/bal-te.bupe16dec16-story.html> (last visited April 13, 2018) (“Though he described Suboxone as a ‘good drug’ for treating addicts, [RADARS executive director Richard] Dart said that buprenorphine enthusiasts tend to minimize abuse.”)
6.
“About Us,”The National Alliance of Advocates for Buprenorphine Treatment, available at <https://www.naabt.org/about_us.cfm> (last visited April 13, 2018).
“Statement from FDA Commissioner Scott Gottlieb, M.D., on the Agency’s Continued Efforts to Promote the Safe Adoption of Medication-Assisted Treatment for Opioid addiction,”U.S. Food and Drug Administration, September, 20, 2017, at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm576752.htm> (last visited April 13, 2018) (committing to “promoting more widespread, safe adoption of MAT as a way to help more people overcome addiction.”)
H.Abadinsky, Drug Use and Abuse: A Comprehensive Introduction (Boston: Cengage Learning, 2017): at 205.
13.
J. H.Jaffe and C.O’Keeffe, “From Morphine Clinics to Buprenorphine: Regulating opioid agonist treatment of addiction in the United States,”Drug and Alcohol Dependence70, no. 2 supplement (2003): S3-S11, at S4; H. Joseph, S. Stancliff, and J. Langrod, “Methadone Maintenance Treatment (MMT): A Review of Historical and Clinical Issues,” Mount Sinai Journal of Medicine 67, no. 5-6 (2000): 347-365, at 348.
14.
S.Quinones, Dreamland: The True Tale of America’s Opiate Epidemic (New York: Bloomsbury Books, 2015): at 63.
Institute of Medicine, Federal Regulation of Methadone Treatment, (Washington, DC: The National Academies Press, 1995): at 95, available at <https://doi.org/10.17226/4899> (last visited April 13, 2018).
22.
Id.
23.
Jaffe and O’Keefe supra note 13 at S5.
24.
Id.
25.
SeeCenter for Substance Abuse Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs, (Rockville, MD), Substance Abuse and Mental Health Services Administration (US), (2005): at 78, available at <https://www.ncbi.nlm.nih.gov/books/NBK64152> (last visited April 13, 2018).
26.
Id. See also 42 C.F.R., § 8.12 (2015).
27.
See e.g. M.Rosenbaum and S.Murphy, “Not the Picture of Health: Women on Methadone,”Journal of Psychoactive Drugs19, no. 2 (1987): 217-226, at 217.
28.
Id.
29.
B.Fischer, J.Rehm, G.Kim, and M.Kirst, “Eyes Wide Shut? – A Conceptual and Empirical Critique of Methadone Maintenance Treatment,”European Addiction Research11, no. 1 (2005): 1-14, at 4.
30.
See L.Manchikanti, “Prescription Drug Abuse: What is Being Done to Address this New Drug Epidemic? Testimony Before the Subcommittee on Criminal Justice, Drug Policy and Human Resources,”Health Policy Review9, no. 4 (2006): 287-321, at 287, 300; see also M. Madden and S. Shapiro, “The Methadone Epidemic: Methadone-Related Deaths on the Rise in Vermont,” American Journal of Forensic Medicine 32, no. 2 (2011): 131-135, at 134.
31.
M.Faul, M.Bohm, and C.Alexander, “Methadone Prescribing and Overdose and the Association with Medicaid Preferred Drug List Policies — United States, 2007–2014,”Morbidity and Mortality Weekly Report 201766, no. 12 (2017): 320–323, available at <http://dx.doi.org/10.15585/mmwr.mm6612a2> (last visited April 13, 2018).
32.
Institute of Medicine, supra note 21 at 10.
33.
Madden and Shapiro, supra note 30.
34.
See I. K.Khanna and S.Pillarisetti, “Buprenorphine – an Attractive Opioid with Underutilized Potential in Treatment of Chronic Pain,”Journal of Pain Research8 (2015): 859–870, 864, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675640> (last visited April 13, 2018).
K. A.Lyseng-Williamson, “Buprenorphine/Naloxone Sublingual Tablet (Zubsolv®): A Guide to its use in the Maintenance Treatment of Opioid Dependence in the USA,”Drugs & Therapy Perspectives29, no. 11 (2013): 336-341.
See N.Guevremont, M.Barnes, and C.Haupt, “Physician Autonomy and the Opioid Crisis,”The Journal of Law, Medicine & Ethics46, no. 2 (2018): 203-219.
42.
H. K.Knudsen, J. R.Havens, M. R.Lofwall, J. L.Studts, and S. L.Walsh, “Buprenorphine Physician Supply: Relationship with State-Level Prescription Opioid Mortality,”Drug and Alcohol Dependence173 (2017): S55-S64, at S56, available at <https://doi.org/10.1016/j.drugalcdep.2016.08.642> (last visited April 13, 2018).
S. L.Walsh, K. L.Preston, M. L.Stitzer, E. J.Cone, and G. E.Bigelow, “Clinical Pharmacology of Buprenorphine: Ceiling Effects at High Doses.”Clinical Pharmacology & Therapeutics55, no. 5 (1994): 569–580, at 579.
M.R.Lofwall and S.Walsh, “A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences from Around the World,”Journal of Addictive Medicine8, no. 5 (2014): 315-326, at 322.
51.
Id. See alsoJ.Ahmadi, K.Ahmadi, and J.Ohaeri, “Controlled, Randomized Trial in Maintenance Treatment of Intravenous Buprenorphine Dependence with Naltrexone, Methadone or Buprenorphine: A Novel Study,”European Journal of Clinical Investigation33, no. 9 (2003): 824–829, at 825.
52.
See Sontag, supra note 7.
53.
A.Nigamet al., “Naloxone-Induced Withdrawal in Patients with Buprenorphine Dependence,”Addiction89, no. 3 (1994): 317-320, at 317-318; Ahmadi, Ahmadi and Ohaeri, supra note 51, at 824; Substance Abuse and Mental Health Services Administration, supra note 45.
54.
H.Uosukainenet al., “Twelve-Year Trend in Treatment Seeking for Buprenorphine Abuse in Finland,”Drug and Alcohol Dependence127, no. 1-3 (2013) 207-214, at 210-211.
SeeB.Vicknasingam, M.Mazlanb, R. S.Schottenfeld, and M.C.Chawarski, “Injection of Buprenorphine and Buprenorphine/Naloxone Tablets in Malaysia,”Drug and Alcohol Dependence111, no. 1-2 (2010): 44–49; at 45; H. Alho, D. Sinclair, E. Vuori, and A. Holopainen, “Abuse Liability of Buprenorphine–Naloxone Tablets in Untreated IV Drug Users,” Drug and Alcohol Dependence 88, no. 1 (2007): 75–78, at 77.
63.
See Vicknasingam, Mazlanb, Schottenfeld, and Chawarski supra note 62.
64.
Dr. Marek Chawarski (Associate Professor of Psychiatry and of Emergency Medicine, Yale School of Medicine), interview with author, October 26, 2017; Id at 44.
65.
See Vicknasingam, Mazlanb, Schottenfeld, and Chawarski supra note 62.
M. A.Yokell, N. D.Zaller, T. C.Green, and J. D.Rich, “Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review,”Current Drug Abuse Reviews4, no. 1 (2011): 28–41, at 33 available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154701> (last visited April 17, 2018).
69.
Simojoki and Alho, supra note 66.
70.
A.Partanen and J.Mäki, “Buprenorphine More Common as a Problem Drug in Finland,”Nordisk Alkohol- & Narkotikatidskrift21 (2004): 156-161, at 159, available at <http://journals.sagepub.com/doi/pdf/10.1177/145507250402101s17> (last visited May 25, 2018).
See S. S.Solomonet al., “The Profile of Injection Drug Users in Chennai, India: Identification of Risk Behaviours and Implications for Interventions,”Substance Use & Misuse45, no. 3 (2010): 354–367, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924430> (last visited April 18, 2018).
A.Casati, R.Sedefov, and T.Pfeiffer-Gerschel, “Misuse of Medicines in the European Union: A Systematic Review of the Literature,”European Addiction Research18 (2012): 228–245, at 241.
79.
Id.
80.
See Substance Abuse and Mental Health Services Administration, supra note 46
81.
Vicknasingam, Mazlanb, Schottenfeld, and Chawarski supra note 62 at 47.
82.
See European Monitoring Centre for Drugs and Drug Addiction, supra note 67, at 67.
83.
European Monitoring Centre for Drugs and Drug Addiction, supra note 46, at 42-43.
84.
Walsh, Preston, Stitzer, Cone, and Bigelow, supra note 44 at 579.
85.
A. J.Saxon, H.Yih-Ing, G.Woody, and W.Ling, “Medication-Assisted Treatment for Opioid Addiction: Methadone and Buprenorphine,”Journal Food Drug Analysis2, no. 4 (2014): S69–S72, at S70.
86.
T. R.Kosten and T. P.George, “The Neurobiology of Opioid Dependence: Implications for Treatment,”Science & Practice Perspectives1, no. 1 (2002): 13–20, at 15, available at <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851054> (last visited April 18, 2018).
European Monitoring Centre for Drugs and Drug Addiction, supra note 46, at 48.
91.
O.Ferrantet al., “Fatal Poisoning Due to Snorting Buprenorphine and Alcohol Consumption,”Forensic Science International204, no. 1-3 (2011): e8-e11, at e10.
92.
R. L.Collins, P. L.Ellickson, and R. M.Bell, “Simultaneous Polydrug Use Among Teens: Prevalence And Predictors,”Journal of Substance Abuse10, no. 3 (1999): 233-253, at 233-234.
S.Harris, “To Be Free and Normal: Addiction, Governance, and the Therapeutics of Buprenorphine,”Medical Anthropology Quarterly29, no. 4 (2015): 512–530, at 521.
96.
Id., see also Genis, supra note 55.
97.
P.Cushman, Jr., “Alcohol and Opioids: Possible Interactions of Clinical Importance,”Advances Alcohol & Substance Abuse6, no. 3 (1987): 33-46, at 41.
S.Varma, S.Balachander, and D.Basu, “Buprenorphine-Induced Psychotic Symptoms: A Case Report,”The Primary Care Companion for CNS Disorders15, no. 4 (2013).
103.
See“Co-occurring Disorders,”Substance Abuse and Mental Health Services Administration, March8, 2016, available at <https://www.samhsa.gov/disorders/co-occurring> (last visited April 18, 2018), Center for Substance Abuse Treatment, supra note 25 at Chapter 12; R. K. Brooner, V. L. King, M. Kidorf, C. W. Schmidt, and G. E. Bigelow, “Psychiatric and Substance Use Comorbidity Among Treatment-Seeking Opioid Abusers,” Archives of General Psychiatry 54, no. 1 (1997): 71–80, at 71.
104.
European Monitoring Centre for Drugs and Drug Addiction, supra note 46, at 38; M.Soyka, B.Hock, S.Kagereret al., “Less Impairment on one Portion of a Driving-Relevant Psychomotor Battery in Buprenorphine-Maintained than in Methadone Maintained Patients,”Journal of Clinical Psycho-pharmacology25, no. 5 (2005): 490-493, at 493.
105.
See e.g. Benyamin, Trescot, and Datta, supra note 87 at S115.
106.
See discussion supra at note 53.
107.
J. D.Allen, M. J.Casavant, H. A.Spilleret al., “Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000–2015,”Pediatrics139, no. 4 (2017): 1-10, available at <http://pediatrics.aappublications.org/content/early/2017/03/16/peds.2016-3382> (last visited April 18, 2018); C. Konijnenberg and A. Melinder, “Prenatal Exposure to Methadone and Buprenorphine: A Review of the Potential Effects on Cognitive Development,” Child Neuropsychology 17, no. 5 (2011): 495–519.
R. P.Mattick, R.Ali, and J. M.White, “Buprenorphine versus Methadone Maintenance Therapy: A Randomized Double-Blind Trial with 405 Opioid-Dependent Patients,”Addiction98, no. 4 (2003): 441–452, at 441.
P.Tice, “Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health,”Substance Abuse and Mental Health Administration, September2017, at 21, available at <https://store.samhsa.gov/shin/content/SMA17-5044/SMA17-5044.pdf> (last visited April 18, 2018).
W.Linget al., “Buprenorphine Tapering Schedule and Illicit Opioid Use,”Addiction104, no. 2 (2009): 256–265, at 257.
136.
S. C.Sigmonet al., “A Randomized, Double-Blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers,”JAMA Psychiatry70, no. 12 (2013): 1347–1354, at 1351.
137.
J. F.Kellyet al., “Prevalence and Pathways of Recovery from Drug and Alcohol Problems in the United States Population: Implications for Practice, Research, and Policy,”Drug and Alcohol Dependence181 (2017): 162-169, at 168, available at <https://doi.org/10.1016/j.drugalcdep.2017.09.028> (last visited April 18, 2018).
Id;“Tapering and Discontinuation of Patients from Buprenorphine,”Buppractice, available at <https://www.buppractice.com/node/12121> (last accessed Jan. 15, 2018); see also R. D. Blondell et al., “A Clinical Trial Comparing Tapering Doses of Buprenorphine With Steady Doses for Chronic Pain and Coexistent Opioid Addiction,” Journal of Addictive Medicine 4, no. 3 (2010): 140-146, at 140.
140.
Buppractice, supra note 139. See alsoP. P.Cassadonte, “Transfer from Methadone to Buprenorphine,”PCSS, August9, 2006, at 3, available at <http://naabt.org/documents/PCSS_Meth-bupe-transfer.pdf> (last visited April 18, 2018).
See e.g., K.Chaiyachati, and J.Hom, “Let’s Put Opioids For Treating Addiction On Equal Footing With Prescribing Opioids For Pain,”Health Affairs, May10, 2016, available at <http://www.healthaffairs.org/do/10.1377/hblog20160510.054813/full> (last visited April 18, 2018).
“FDA Approves First Once-Monthly Buprenorphine Injection, a Medication-Assisted Treatment Option for Opioid use Disorder,”U.S. Food and Drug Administration, November30, 2017, available at <https://www.fda.gov/NewsEvents/News-room/PressAnnouncements/ucm587312.htm> (last visited April 18, 2018).
Interview with Dr. Chawarski, supra note 64; see alsoA. I.Leshner, “Science-Based Views of Drug Addiction and Its Treatment,”JAMA282, no. 14 (1999): 1314-1316, at 1316. But see K. M. Carroll and R. Weiss, “The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review,” American Journal of Psychiatry 174, no. 8 (2017): 738-747, at 745, available at <https://www.ncbi.nlm.nih.gov/pubmed/27978771> (last visited April 18, 2018).
152.
“Statement from FDA Commissioner Scott Gottlieb,” supra note 8.
